The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Inactivated Vaccine-Global Market Insights and Sales Trends 2025
Synopsis
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global Inactivated Vaccine market size is expected to reach US$ 7544 million by 2029, growing at a CAGR of 3.3% from 2023 to 2029. The market is mainly driven by the significant applications of Inactivated Vaccine in various end use industries. The expanding demands from the Hospital and Medical Center, are propelling Inactivated Vaccine market. Children Inactivated Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adult Inactivated Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Inactivated Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Inactivated Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Inactivated Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Inactivated Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Inactivated Vaccine covered in this report include Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.) and Sanofi Pasteur(France), etc.
The global Inactivated Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma(Japan)
CSL Limited(Australia)
Emergent BioSolutions(U.S.)
GlaxoSmithKline(U.K.)
Johnson & Johnson(U.S.)
MedImmune(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
Sanofi Pasteur(France)
Serum Institute of India Pvt(India)
Global Inactivated Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Inactivated Vaccine market, Segment by Type:
Children Inactivated Vaccine
Adult Inactivated Vaccine
Global Inactivated Vaccine market, by Application
Hospital
Medical Center
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Inactivated Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global Inactivated Vaccine market size is expected to reach US$ 7544 million by 2029, growing at a CAGR of 3.3% from 2023 to 2029. The market is mainly driven by the significant applications of Inactivated Vaccine in various end use industries. The expanding demands from the Hospital and Medical Center, are propelling Inactivated Vaccine market. Children Inactivated Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Adult Inactivated Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Inactivated Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Inactivated Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Inactivated Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Inactivated Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Inactivated Vaccine covered in this report include Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.) and Sanofi Pasteur(France), etc.
The global Inactivated Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma(Japan)
CSL Limited(Australia)
Emergent BioSolutions(U.S.)
GlaxoSmithKline(U.K.)
Johnson & Johnson(U.S.)
MedImmune(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
Sanofi Pasteur(France)
Serum Institute of India Pvt(India)
Global Inactivated Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Inactivated Vaccine market, Segment by Type:
Children Inactivated Vaccine
Adult Inactivated Vaccine
Global Inactivated Vaccine market, by Application
Hospital
Medical Center
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Inactivated Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Inactivated Vaccine
1.1 Inactivated Vaccine Market Overview
1.1.1 Inactivated Vaccine Product Scope
1.1.2 Inactivated Vaccine Market Status and Outlook
1.2 Global Inactivated Vaccine Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Inactivated Vaccine Market Size by Region (2018-2029)
1.4 Global Inactivated Vaccine Historic Market Size by Region (2018-2023)
1.5 Global Inactivated Vaccine Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Inactivated Vaccine Market Size (2018-2029)
1.6.1 North America Inactivated Vaccine Market Size (2018-2029)
1.6.2 Europe Inactivated Vaccine Market Size (2018-2029)
1.6.3 Asia-Pacific Inactivated Vaccine Market Size (2018-2029)
1.6.4 Latin America Inactivated Vaccine Market Size (2018-2029)
1.6.5 Middle East & Africa Inactivated Vaccine Market Size (2018-2029)
2 Inactivated Vaccine Market by Type
2.1 Introduction
2.1.1 Children Inactivated Vaccine
2.1.2 Adult Inactivated Vaccine
2.2 Global Inactivated Vaccine Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Inactivated Vaccine Historic Market Size by Type (2018-2023)
2.2.2 Global Inactivated Vaccine Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Inactivated Vaccine Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Inactivated Vaccine Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Inactivated Vaccine Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Inactivated Vaccine Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Inactivated Vaccine Revenue Breakdown by Type (2018-2029)
3 Inactivated Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Medical Center
3.2 Global Inactivated Vaccine Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Inactivated Vaccine Historic Market Size by Application (2018-2023)
3.2.2 Global Inactivated Vaccine Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Inactivated Vaccine Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Inactivated Vaccine Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Inactivated Vaccine Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Inactivated Vaccine Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Inactivated Vaccine Revenue Breakdown by Application (2018-2029)
4 Inactivated Vaccine Competition Analysis by Players
4.1 Global Inactivated Vaccine Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2022)
4.3 Date of Key Players Enter into Inactivated Vaccine Market
4.4 Global Top Players Inactivated Vaccine Headquarters and Area Served
4.5 Key Players Inactivated Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Inactivated Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astellas Pharma(Japan)
5.1.1 Astellas Pharma(Japan) Profile
5.1.2 Astellas Pharma(Japan) Main Business
5.1.3 Astellas Pharma(Japan) Inactivated Vaccine Products, Services and Solutions
5.1.4 Astellas Pharma(Japan) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.1.5 Astellas Pharma(Japan) Recent Developments
5.2 CSL Limited(Australia)
5.2.1 CSL Limited(Australia) Profile
5.2.2 CSL Limited(Australia) Main Business
5.2.3 CSL Limited(Australia) Inactivated Vaccine Products, Services and Solutions
5.2.4 CSL Limited(Australia) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.2.5 CSL Limited(Australia) Recent Developments
5.3 Emergent BioSolutions(U.S.)
5.3.1 Emergent BioSolutions(U.S.) Profile
5.3.2 Emergent BioSolutions(U.S.) Main Business
5.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Products, Services and Solutions
5.3.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline(U.K.) Recent Developments
5.4 GlaxoSmithKline(U.K.)
5.4.1 GlaxoSmithKline(U.K.) Profile
5.4.2 GlaxoSmithKline(U.K.) Main Business
5.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Products, Services and Solutions
5.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline(U.K.) Recent Developments
5.5 Johnson & Johnson(U.S.)
5.5.1 Johnson & Johnson(U.S.) Profile
5.5.2 Johnson & Johnson(U.S.) Main Business
5.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Products, Services and Solutions
5.5.4 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson(U.S.) Recent Developments
5.6 MedImmune(U.S.)
5.6.1 MedImmune(U.S.) Profile
5.6.2 MedImmune(U.S.) Main Business
5.6.3 MedImmune(U.S.) Inactivated Vaccine Products, Services and Solutions
5.6.4 MedImmune(U.S.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.6.5 MedImmune(U.S.) Recent Developments
5.7 Merck & Co(U.S.)
5.7.1 Merck & Co(U.S.) Profile
5.7.2 Merck & Co(U.S.) Main Business
5.7.3 Merck & Co(U.S.) Inactivated Vaccine Products, Services and Solutions
5.7.4 Merck & Co(U.S.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.7.5 Merck & Co(U.S.) Recent Developments
5.8 Pfizer(U.S.)
5.8.1 Pfizer(U.S.) Profile
5.8.2 Pfizer(U.S.) Main Business
5.8.3 Pfizer(U.S.) Inactivated Vaccine Products, Services and Solutions
5.8.4 Pfizer(U.S.) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.8.5 Pfizer(U.S.) Recent Developments
5.9 Sanofi Pasteur(France)
5.9.1 Sanofi Pasteur(France) Profile
5.9.2 Sanofi Pasteur(France) Main Business
5.9.3 Sanofi Pasteur(France) Inactivated Vaccine Products, Services and Solutions
5.9.4 Sanofi Pasteur(France) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.9.5 Sanofi Pasteur(France) Recent Developments
5.10 Serum Institute of India Pvt(India)
5.10.1 Serum Institute of India Pvt(India) Profile
5.10.2 Serum Institute of India Pvt(India) Main Business
5.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Products, Services and Solutions
5.10.4 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue (US$ Million) & (2018-2023)
5.10.5 Serum Institute of India Pvt(India) Recent Developments
6 North America
6.1 North America Inactivated Vaccine Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Inactivated Vaccine Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Inactivated Vaccine Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Inactivated Vaccine Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Inactivated Vaccine Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Inactivated Vaccine Market Dynamics
11.1 Inactivated Vaccine Industry Trends
11.2 Inactivated Vaccine Market Drivers
11.3 Inactivated Vaccine Market Challenges
11.4 Inactivated Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
